University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage.
The goal of QR-02 is to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia, an outcome that would mark a significant breakthrough in oral medicine. By ...
The "Strategic Intelligence: Orphan Designated Drugs" report has been added to ResearchAndMarkets.com's offering.This report consolidates the latest thinking and forecasts around how the healthcare, ...